We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mitochondrial Proteins Implicated in Neurodegenerative Disorders

By Biotechdaily staff writers
Posted on 05 Sep 2007
Nervous-system researchers have found that the slow Wallerian degeneration gene modifies the expression of at least 16 proteins including eight that are regulators of mitochondrial stability and degeneration. More...


When a nerve axon is cut or crushed, the nerve fibers in the distal part of the axon, separated from the cell body, undergo a form of spontaneous degeneration, known as Wallerian degeneration. Furthermore, neurons are primary pathologic targets in many neurodegenerative conditions, ranging from Alzheimer disease to motor neuron disease. Axons and synapses are protected from degeneration by the slow Wallerian degeneration (Wlds) gene.

Investigators at the University of Edinburgh (UK) used differential proteomics analysis to identify proteins whose expression levels were significantly altered in isolated synaptic preparations from the striatum of Wlds mice. Results published in the August 2007 issue of the journal Molecular & Cellular Proteomics revealed that eight of the 16 proteins that modified expression levels in Wlds synapses were known regulators of mitochondrial stability and degeneration. Of the non-mitochondrial proteins identified, several had been implicated in neurodegenerative diseases where synapses and axons were primary pathologic targets.

The investigators concluded that, "Altered mitochondrial responses to degenerative stimuli are likely to play an important role in the neuroprotective Wlds phenotype and that targeting proteins identified in the current study may lead to novel therapies for the treatment of neurodegenerative diseases in humans.”


Related Links:
University of Edinburgh

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.